KAIST scientists have created a fast-acting, stable powder hemostat that stops bleeding in one second and could significantly improve survival in combat and emergency medicine.
Severe blood loss remains the primary cause of death from combat injuries. To address this challenge, a research team at KAIST that included an active duty Army Major set out to develop a faster and more reliable way to stop bleeding.
Their work led to a next-generation powder-type hemostatic agent that can halt bleeding within one second when sprayed directly onto a wound, offering a potential breakthrough for saving lives on the battlefield.
A spray-on solution in seconds
On December 29th, KAIST announced that a joint team led by Professor Steve Park of the Department of Materials Science and Engineering and Professor Sangyong Jon of the Department of Biological Sciences had created a powder based hemostatic agent that rapidly forms a strong hydrogel barrier. When applied to an injured area, the material transforms within about one second, sealing the wound almost immediately.
The researchers designed the technology with real combat conditions in mind, and the direct involvement of an Army Major helped ensure its practical readiness. The agent hardens instantly even in harsh environments such as battlefields and disaster zones, and its stability during storage allows it to be deployed quickly for emergency treatment.

Why existing hemostats fall short
Traditional patch-type hemostatic products commonly used in medicine struggle to treat deep or irregular wounds because of their flat shape. These materials are also sensitive to heat and moisture, which limits how easily they can be stored and used in demanding settings.
To overcome these limitations, the KAIST team developed the hemostatic agent in a powder form that can be applied to wounds of many shapes and sizes, including those that are deep or uneven. A single formulation can be used across a wide range of injury types, improving flexibility in emergency care.
Existing powder hemostatic agents had limits in hemostatic capability as they functioned by physically absorbing blood to form a barrier. To solve this problem, the research team focused on the ionic reactions within the blood.
The 'AGCL powder' developed this time has a structure that combines biocompatible natural materials such as Alginate and Gellan Gum (which react with calcium for ultra-fast gelation and physical sealing) and Chitosan (which bonds with blood components to enhance chemical and biological hemostasis). It reacts with cations such as calcium in the blood to turn into a gel state in one second, instantly sealing the wound.
Strength, safety, and regeneration
Furthermore, by forming a three-dimensional structure inside the powder, it can absorb blood amounting to more than 7 times its own weight (725%). Due to this, it quickly blocks blood flow even in high-pressure and excessive bleeding situations, and showed superior sealing performance compared to commercial hemostatic agents with a high adhesive strength of over '40kPa', a level of pressure that can withstand being pressed strongly by hand.

AGCL powder is composed entirely of naturally derived materials, showing a hemolysis rate of less than 3%, a cell viability rate of over 99%, and an antibacterial effect of 99.9%, making it safe even when in contact with blood. In animal experiments, excellent tissue regeneration effects such as rapid wound recovery and promotion of blood vessel and collagen regeneration were confirmed.
Proven performance under stress
In surgical liver injury experiments, the amount of bleeding and hemostasis time were significantly reduced compared to commercial hemostatic agents, and liver function recovered to normal levels two weeks after surgery. No abnormal findings were observed in systemic toxicity evaluations.
In particular, this hemostatic agent maintains its performance for two years even in room temperature and high humidity environments, possessing the advantage of being ready for immediate use in harsh environments such as military operation sites or disaster areas.
From defense research to civilian care
Although this research is an advanced new material technology developed with national defense purposes in mind, it has great potential for application throughout emergency medicine, including disaster sites, developing countries, and medically underserved areas.

It is evaluated as a representative spin-off case where national defense science and technology expanded to the private sector, as it is capable of everything from emergency treatment on the battlefield to internal surgical hemostasis.
Spin-off case: Expanding or transferring national defense science and technology for use in the private sector. Examples include computers, GPS, microwave ovens, etc.
This study was recognized for its scientific innovation and national defense utility simultaneously, winning the 2025 KAIST Q-Day President's Award and the Minister of National Defense Award at the 2024 KAIST-KNDU National Defense Academic Conference.
Ph.D candidate Kyusoon Park (Army Major), who participated in the research, stated, "The core of modern warfare is minimizing the loss of human life," and added, "I started the research with a sense of mission to save even one more soldier." He continued, "I hope this technology will be used as a life-saving technology in both national defense and private medical fields."
Reference: "An Ionic Gelation Powder for Ultrafast Hemostasis and Accelerated Wound Healing" by Youngju Son, Kyusoon Pak, Taehoon Lee, Monica Celine Prayogo, Jinyoung Choi, Sukkyung Kang, Minjoo Kang, Byungkook Oh, Sang Yu Sun, Sanha Kim, Sung Gap Im, Sangyong Jon and Steve Park, 28 October 2025, Advanced Functional Materials.
DOI: 10.1002/adfm.202523910
Support of the National Research Foundation of Korea (NRF).
News
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
3D Human Brain Tissue Model Replicates Alzheimer’s Pathology
Summary: Researchers introduced a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. Developed over nine years using human stem cells, the self-organizing tissue spheroids integrate functional neurons, [...]















